1. Home
  2. News
  3. Meetings and Workshops
  4. Fourth Artificial Pancreas Workshop: Testing and Adoption of Current and Emerging Technologies
Banner for the 2016 Fourth Artificial Pancreas Workshop: Testing and Adoption of Current and Emerging Technologies.

Fourth Artificial Pancreas Workshop: Testing and Adoption of Current and Emerging Technologies

July 6 - 7, 2016 Location Contacts
Event Details Agenda

Event Details

Event Details

Current evidence demonstrates that when glycemic control is not optimized, diabetes imposes additional burdensome care requirements, health care costs, and high risk of disabling complications. It is expected that close-to-physiological-glucose metabolic control provided by an automated glucose responsive hormone delivery system (artificial pancreas) will reduce the incidence of acute and chronic complications and significantly improve the quality of life of affected individuals and caretakers. As a consequence, further morbidity and mortality may also be prevented.

Meeting Objectives

The purpose of this workshop is to discuss in a multi-disciplinary forum the actual and potential future challenges for the testing of current and emerging systems and their components, including integration strategies, clinical testing modalities, psychosocial and usability factors, regulatory and reimbursement considerations, and prospective areas of research to accelerate the availability of a wearable, affordable, and user-friendly artificial pancreas (AP) for individuals with diabetes. Some of the topics to be discussed are:

  • Testing of automated glucose control systems (AGCS): lessons and challenges
  • Personalization of AP platforms
  • Psychosocial drivers and barriers
  • Interoperability of platforms/components: What is needed for plug-and-play capability?
  • Data management and cybersecurity
  • Emerging technologies to improve sensing and hormone delivery
  • Strategies to facilitate the development of a viable commercial platform

This workshop has been organized in coordination with the Diabetes Mellitus Interagency Coordinating Committee (DMICC)

Organizing Committee

Guillermo Arreaza-Rubín, M.D.
Director, Diabetes Technology Program
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health

Stayce Beck, Ph.D., M.P.H.
Chief, Diabetes Diagnostic Devices Branch
Office of In Vitro Diagnostic Devices and Radiological Health
Center for Devices and Radiological Health
U.S. Food and Drug Administration

Andrew Bremer, M.D., Ph.D.
Program Director
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health

Vincent Crabtree, Ph.D.
Director, Research Business and New Technology Development
JDRF

Campbell Hutton
Senior Director, Regulatory Affairs
JDRF

David C. Klonoff, M.D.
Medical Director, Diabetes Research Institute
Mills-Peninsula Health Services

Aaron Kowalski, Ph.D.
Chief Mission Officer and Vice President, Research
JDRF

Courtney Lias, Ph.D.
Director, Division of Chemistry and Toxicology Devices
Office of In Vitro Diagnostic Devices and Radiological Health
Center for Devices and Radiological Health
U.S. Food and Drug Administration

David Panzirer
Trustee
The Leona M. and Harry B. Helmsley Charitable Trust

Sean Sullivan, Ph.D.
Senior Program Officer, Type 1 Diabetes
The Leona M. and Harry B. Helmsley Charitable Trust

Yiduo Wu, Ph.D.
Artificial Pancreas Team Lead
Office of In Vitro Diagnostic Devices and Radiological Health
Center for Devices and Radiological Health
U.S. Food and Drug Administration

Registration Deadline

July 5, 2016